Prostate Cancer

Morgans Addresses Neuropathic Toxicity in Second-Line Metastatic CRPC

September 24, 2020

Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old male with metastatic castration-resistant prostate cancer.

Early Efficacy Observed With Novel BiTE Immune-Oncology Agent in mCRPC

September 21, 2020

AMG 160 showed preliminary evidence of efficacy with a manageable safety profile as treatment of patients with metastatic castration-resistant prostate cancer who have been heavily pretreated.

Ipatasertinib Combo Prolongs PFS in PTEN-Loss mCRPC

September 21, 2020

A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.

OS With Olaparib Bests Androgen Receptor Inhibitors in Certain Men With mCRPC

September 20, 2020

Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.

PARP Inhibitors Gain Indications in Advanced Prostate Cancer

September 15, 2020

PARP inhibitors have propelled the field of metastatic castration-resistant prostate cancer forward as the next class of therapeutics to advance outcomes.

FDA Grants Fast Track Designation to Novel Androgen Receptor in mCRPC

September 14, 2020

A Fast Track designation has been granted by the FDA to EPI-7386, a selective androgen receptor inhibitor, which is a potential treatment for adult patients with metastatic castration-resistant prostate cancer that is resistant to standard-of-care therapy.

Final ARAMIS Data Confirm Darolutamide Efficacy Benefit in nmCRPC

September 11, 2020

A higher percentage of patients with nonmetastatic castration-resistant prostate cancer were alive at 3 years on treatment with darolutamide compare with placebo, according to published results from the final analysis of the phase 3 ARAMIS clinical trial.

Phase1b Trial Investigates Atezolizumab and Radium-223 in mCRPC

September 03, 2020

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

LuPSMA May Fill Gap in Advanced Prostate Cancer After Exhaustion of Standard Treatments

August 31, 2020

In an interview with Targeted Oncology, Andrei Gafita, MD, discussed the recent findings from the international multicenter retrospective analysis of LuPSMA as treatment of patients with metastatic castration-resistant prostate cancer, and how these findings and more clinical trials could lead to the approval of this treatment for patients who have exhausted all other standard treatments.

Efstathiou Compares the Efficacy and Safety of AR Inhibitors in Nonmetastatic CRPC

August 31, 2020

During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, a discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer.